Professor Harrington studied Medicine at St Bartholomew’s Hospital in London and began focusing on head and neck cancer as a PhD student at Hammersmith Hospital. He completed his postdoctoral research in molecular medicine at the Mayo Clinic, Minnesota.
Besides being an expert in the use of radiotherapy and chemoradiotherapy, he is a specialist on drug treatment of relapsed and metastatic head and neck cancer. He is a Professor in Biological Cancer Therapies at The Institute of Cancer Research (ICR), where he is also the Targeted Therapy Team Leader in the Division of Cancer Biology. He has two main areas of research interest: oncolytic virotherapy (which comprises the use of genetically modified viruses as selective cancer therapeutic) and the development of new drugs that improve the activity of radiation against cancer cells. Professor Harrington was appointed as Joint Head of the ICR’s Division of Radiotherapy and Imaging in 2013.
He is also a Consultant Clinical Oncologist at The Royal Marsden NHS Foundation. Much of Professor Harrington’s laboratory work is immediately translated into clinical trials at The Royal Marsden, most often in patients with head and neck cancers and melanomas.